MET and VEGF: synergistic targets in castration-resistant prostate cancer

Abstract A13: Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184

(2012) B. Sennino et al.   MOLECULAR CANCER THERAPEUTICS

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis

(2011) Weon-Kyoo You et al.   BMB Reports

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

(2011) W.-K. You et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Castration-Resistant Prostate Cancer: Targeted Therapies

(2011) S. Leo et al.   CHEMOTHERAPY

Circulating Tumor Cells as Biomarkers in Prostate Cancer

(2011) D. C. Danila et al.   CLINICAL CANCER RESEARCH

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment

(2010) Johannes C. Reichert et al.   BIOMATERIALS

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

Targeting the HGF/Met signalling pathway in cancer

(2010) Fabiola Cecchi et al.   EUROPEAN JOURNAL OF CANCER

Computer-aided molecular design of 1H-imidazole-2,4-diamine derivatives as potential inhibitors of Plasmodium falciparum DHFR enzyme

(2010) Legesse Adane et al.   JOURNAL OF MOLECULAR MODELING

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells

(2010) Shumin Zhang et al.   Molecular Cancer

The immunolocalization and possible role of c-Met (MET, hepatic growth factor receptor) in the developing human fetal mandibular condyle

(2009) Rosalia Leonardi et al.   ACTA HISTOCHEMICA

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

(2009) G. Sonpavde et al.   ANNALS OF ONCOLOGY

Phase II study of sunitinib in men with advanced prostate cancer

(2009) M. Dror Michaelson et al.   ANNALS OF ONCOLOGY

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer

(2009) Jeanny B. Aragon-Ching et al.   BJU INTERNATIONAL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence

(2009) T. M. Morgan et al.   CLINICAL CANCER RESEARCH

Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF

(2009) Ernestina Schipani et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

(2009) Maha Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

(2009) Howard I Scher et al.   LANCET ONCOLOGY

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

(2008) D. Olmos et al.   ANNALS OF ONCOLOGY

Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer

(2008) Yoshihiko Kitajima et al.   CANCER SCIENCE

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study

(2008) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

Bone Formation During Distraction Osteogenesis Is Dependent on Both VEGFR1 and VEGFR2 Signaling

(2008) Kimberly A Jacobsen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY